Clinical Trial

INTERACT Stomach-II

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase II study conducted in three hospitals in the Netherlands (Erasmus MC in Rotterdam, Catharina Hospital in Eindhoven, and the Netherlands Cancer Institute in Amsterdam). A total of 55 patients will take part. The aim is to test whether a new combination treatment is feasible for patients with gastric peritoneal metastases (PM). The treatment includes chemotherapy (intraperitoneal irinotecan and standard systemic therapy such as CAPOX or FOLFOX), and may also include nivolumab or trastuzumab, depending on biomarker results.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-18.
Status change: Not Yet Recruiting → Recruiting 2026-05-28
Trial Details
NCT Number NCT07133490
Lead Sponsor Erasmus Medical Center
Collaborators: Catharina Ziekenhuis Eindhoven, The Netherlands Cancer Institute
Conditions Peritoneal Metastases From Gastric Cancer
Enrollment 55 participants
Start Date 2025-10-01
Primary Completion 2027-10-01 (estimated)
Study Completion 2028-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-01